0001628280-26-031649
SEC filingInfuSystem Holdings reported Q1 2026 net revenue of $33.7 million (down 3% YoY), net income of $1.0 million ($0.05 diluted EPS), and Adjusted EBITDA of $6.4 million (18.9% margin), reaffirming full-year 2026 guidance amid strategic GE Healthcare contract restructuring and ERP go-live on March 1, 2026.
InfuSystem delivered a strategically focused Q1 2026, where top-line contraction masked underlying operational improvement: GAAP revenue declined 3% YoY to $33.7 million, but this was entirely attributable to the planned $1.6 million reduction from the restructured GE Healthcare biomedical services contract — a decision management explicitly characterized as value-accretive due to disproportionate expense savings. The result was flat Adjusted EBITDA ($6.4M) and a meaningful 320-basis-point gross margin expansion to 58.4%, driven by higher margins in both segments: Patient Services (64.8%, +1.3 pp) benefited from lower pump disposal/maintenance costs, while Device Solutions (46.3%, +3.4 pp) gained from reduced personnel, parts, and travel under the new GE agreement. Patient Services revenue grew 6% YoY to $22.1 million, fueled by explosive 116% growth in Wound Care ($2.1M), now representing 6% of total revenue and anchored by two new compression device supplier relationships — Pneumatic Compression Devices (launched Q3 2025) and Adjustable Compression Wraps (launched Q1 2026). Device Solutions revenue fell 17% YoY to $11.6 million, reflecting not only the GE impact but also a $1.0 million decline in equipment sales tied to a large customer rental buyout that inflated prior-year comparables. Net income turned positive at $1.0 million ($0.05 diluted EPS) versus a $0.3 million loss, aided by lower G&A (down $0.5M YoY, excluding a $1.0M one-time severance in Q1 2025) despite $0.4M in ERP-related IT upgrade costs. Management highlighted the March 1, 2026 ERP go-live as transformational, citing integrated data, standardized workflows, and expected benefits in productivity, pricing insight, fleet utilization, and working capital — positioning the company for scalable growth. With $57.1 million in liquidity and reaffirmed full-year guidance, the quarter reflects disciplined execution of a profitability-over-revenue strategy, validated by stable Adjusted EBITDA and expanding margins despite intentional revenue headwinds.